Zomedica Q1 revenue up 45% to $5.5M; net loss widens to $6.4M

Zomedica Corp.

2023-Q1 EPS reported -$0.01 revenue$5,482,000

Revenue $5.5M (+45% YoY); gross margin 70%; net loss $6.4M ($0.007/share) vs $3.9M loss a year ago.
Diagnostic segment revenue $0.4M (+300% YoY); Therapeutic segment $5.1M (+38% YoY).
Cash and securities $147.5M; cash used in Q1 was $8.3M including $4.0M TRUFORMA licensing fees.
Paid $250k non-refundable deposit to exercise acquisition option for Structured Monitoring Products (VetGuardian).
Amended Georgia lease to add 6,000 sq ft for TRUFORMA cartridge manufacturing; TRUVIEW digital microscopy system launch planned in Q2.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zomedica Corp. reported three months ended March 31, 2023 results: revenue $5.5 million.

Period: three months ended March 31, 2023
Revenue: $5.5 million
Result: reported results

Exact text from the filing

Revenue for the first quarter of 2023 was $5.5 million

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-23-006220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.